The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies
The master agreement is structured to enable UCSF researchers to propose candidate drug targets or compelling biology relevant to the identification, prevention, treatment or amelioration of human diseases with underlying immune dysfunction.
- The master agreement is structured to enable UCSF researchers to propose candidate drug targets or compelling biology relevant to the identification, prevention, treatment or amelioration of human diseases with underlying immune dysfunction.
- Foundery’s team of highly experienced and accomplished scientists subsequently conduct translational research on prioritized candidate targets in Foundery’s internal laboratories.
- The master agreement is designed to enhance collaboration and develop impactful therapeutics between UCSF, participating scientists, and Foundery.
- They receive financial rewards if our work on their programs is successful and also benefit from the overall success of Foundery’s portfolio.